Genetic blood disorders are a major public health challenge One of the most serious inherited blood disorders in Ghana is ...
The B-FREE Chronic Babesiosis Study ( NCT06656351) is a Phase 2 open-label study that will evaluate the efficacy (and safety) of the ARAKODA ® regimen of tafenoquine over 90 days for resolution of ...
Breakthrough Therapy Designation request has been submitted to FDA Company to request a Type B meeting with FDA in early 2026 to discuss requirements for a supplementary New Drug Application (sNDA) ...
Company engaged patients diagnosed with chronic babesiosis via social media in a nationwide naming competition A $5K donation from the Company was split between ILADEF and GLA to recognize the winning ...
New Drug Application intended for 2026, subject to generation of positive data from three U.S. clinical trials planned or in progress Total addressable market (TAM) for ARAKODA for Human Babesiosis is ...
The declining efficacy and widespread resistance to antimalarial drugs (AMD) pose significant challenges to global malaria control and elimination efforts. To enhance treatment efficacy, the World ...
New 8-count bottles now available through major retail pharmacies ARAKODA® is the only weekly prophylactic therapy to provide protection against the blood and liver stages of malaria WASHINGTON, June ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results